Ireland-headquartered generics major Actavis (NYSE: ACT) confirmed that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval to market a methylphenidate for extended-release oral suspension.
Actavis' ANDA product is a generic version of US pharma giant Pfizer (NYSE: PFE) and drug delivery specialist Tris Pharma's Quillivant XR, which is a central nervous system stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD).
Law suit instigated by Tris Pharma
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze